Results 51 to 60 of about 1,941 (170)

Internal Consistency of the Hadlock Estimated Fetal Weight Reference: Methodological Analysis

open access: yesBJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Objective To assess the internal consistency of the Hadlock normal range for estimated fetal weight (EFW) and its clinical implications. Design Methodological analysis and retrospective observational audit. Setting Tertiary maternity hospital in Oxford, UK. Population Women with a non‐anomalous singleton pregnancy.
Theophilus K. Adu‐Bredu   +4 more
wiley   +1 more source

Inverting the BTK-BCL2 order [PDF]

open access: yesBlood, 2020
In this issue of Blood, Lin et al report the first long-term follow-up data showing that Bruton tyrosine kinase inhibitors (BTKi's) are effective in chronic lymphocytic leukemia (CLL) after previous progression on venetoclax.
openaire   +2 more sources

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

open access: yesBritish Journal of Haematology, EarlyView.
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa   +25 more
wiley   +1 more source

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model

open access: yesScientific Reports, 2017
BTK plays a critical role in the B cell receptor mediated inflammatory signaling in the rheumatoid arthritis (RA). Through a rational design approach we discovered a highly selective and potent BTK kinase inhibitor (CHMFL-BTK-11) which exerted its ...
Hong Wu   +21 more
doaj   +1 more source

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

open access: yesBritish Journal of Haematology, EarlyView.
Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of
Thérèse Aurran‐Schleinitz   +45 more
wiley   +1 more source

Előszó a tematikus blokkhoz

open access: yesElpis, 2017
Idestova két és fél éve hunyt el fiatalon, tragikus hirtelenséggel Losonczi Péter barátunk, filozófustársunk. Az Elpis jelen száma a Péter emlékére rendezett magyar nyelvű konferencia előadásaiból közöl válogatást.
Gábor Boros, Miklós Vassányi
doaj  

Ibrutinib and standard immunochemotherapy in younger, high‐risk patients with diffuse large B‐cell lymphoma: A phase II study of GLA

open access: yesBritish Journal of Haematology, EarlyView.
Summary Younger patients with high‐risk diffuse large B‐cell lymphoma (DLBCL) frequently have unfavourable outcomes. We conducted a prospective phase II study evaluating ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R‐CHOEP+I) in patients aged 18–60 years with DLBCL and age‐adjusted international prognostic index ≥2.
Evgenii Shumilov   +19 more
wiley   +1 more source

Complex karyotype and non‐BTK driver mutations associated with BTK inhibitor resistance in chronic lymphocytic leukaemia

open access: yesBritish Journal of Haematology, EarlyView.
This graphical abstract illustrates the genetic status in chronic lymphocytic leukaemia (CLL) patients with or without progression on Bruton tyrosine kinase (BTK) inhibitors. It highlights universal clonal evolution, where 100% of progressive disease cases acquired BTK or TP53 mutations.
Kiyomi Mashima   +20 more
wiley   +1 more source

Ismétlés és innováció drámai művekben

open access: yesDigitális Bölcsészet
Tanulmányunkban egy olyan módszert ismertetünk, amellyel drámai szereplők megszólalásainak hírértéke mérhető össze kvantitatív módon. Innovatívnak tekinthető minden olyan szereplő, aki gyakran dolgoz ki a korábbiaktól eltérő jelentést; fenntartó vagy ...
Botond Szemes, Mihály Nagy
doaj   +1 more source

CD20 antigen loss post‐venetoclax/anti‐CD20 therapy in chronic lymphocytic leukaemia: Frequency, characteristics and potential therapeutic implications

open access: yesBritish Journal of Haematology, EarlyView.
Summary Venetoclax plus anti‐CD20 monoclonal antibody (mAb) regimens have revolutionised treatment for chronic lymphocytic leukaemia (CLL); however, CD20 antigen loss is a potential consequence. Given emerging roles for re‐treatment with venetoclax plus anti‐CD20 mAb and CD20‐targeting bispecific antibodies in CLL, we retrospectively assessed the ...
Tamasine Stewart   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy